Health Groups Challenge Philip Morris' IQOS Claims Amid Regulatory Scrutiny

Health campaigners have written to U.S. regulators accusing Philip Morris International (PMI) of misrepresenting past regulatory decisions to market its heated tobacco device IQOS. The campaigners argue that PMI made deceptive claims about reduced health risks, seeking to influence the FDA's approval process for the device in the U.S.

Health campaigners have raised flags to U.S. regulators, alleging that Philip Morris International (PMI) has misrepresented past regulatory decisions to promote its heated tobacco device IQOS. The campaign seeks to thwart PMI's efforts to launch IQOS in the United States.

The Campaign for Tobacco-Free Kids, the American Academy of Pediatrics, and the American Lung Association are among the six health groups that voiced their opposition to the FDA, accusing PMI of making misleading statements suggesting that IQOS reduces disease risk. Their claims reference diverse incidents across the U.S., the Philippines, Mexico, and Kazakhstan.

In response, PMI maintains that its communications adhere to the FDA's regulatory guidelines. Despite ongoing debates, the FDA has yet to decide on imminent applications from PMI aimed at re-approving existing modifications and marketing a newer IQOS version in the U.S. market.

(With inputs from agencies.)